Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries.
OBJECTIVE
Recent data indicate that intraluminal irradiation of coronary arteries following balloon angioplasty reduces proliferation of smooth muscle cells, neointima formation, and restenosis. We present calculations for various isotopes and geometries in an attempt to identify suitable source designs for such treatments.


METHODS
Analytical calculations of dose distributions and dose rates are presented for 192Ir, 125I, 103Pd, 32P, and 90Sr for use in intracoronary irradiation. The effects of source geometry and positioning accuracy are studied.


RESULTS
Accurate source centering, high dose rate, well-defined treatment volume, and radiation safety are all of concern; 15-20 Gy are required to a length of 2-3 cm of vessel wall (2-4 mm diameter). Dose must be confined to the region of the angioplasty, with reduced doses to normal tissues. Beta emitters have radiation safety advantages, but may not have suitable ranges for treating large diameter vessels. Gamma emitters deliver larger doses to normal tissues and to staff. Low energy x-ray emitters such as 125I and 103Pd reduce these risks but are not available at high enough activities. The feasibility of injecting a radioactive liquid directly into the angioplasty balloon is also explored.


CONCLUSIONS
Accurate source centering is found to be of great importance. If this can be accomplished, then high energy beta emitters such as 90Sr would be ideal sources. Otherwise, gamma emitters such as 192Ir may be optimal. A liquid beta source would have optimal geometry and dose distribution, but available sources, such as 32P are unsafe for use with available balloon catheters.
Amols
H I
HI
Columbia University, Department of Radiation Oncology, New York, NY 10032, USA.
Zaider
M
M
Weinberger
J
J
Ennis
R
R
Schiff
P B
PB
Reinstein
L E
LE
D001918:Brachytherapy; D003327:Coronary Disease / Q000532:radiotherapy* / Q000628:therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D007496:Iridium Radioisotopes / Q000008:administration & dosage; D008955:Models, Cardiovascular; D010165:Palladium / Q000008:administration & dosage; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage; D011868:Radioisotopes / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D012008:Recurrence; D013326:Strontium Radioisotopes / Q000008:administration & dosage
D007457:Iodine Radioisotopes; D007496:Iridium Radioisotopes; D010761:Phosphorus Radioisotopes; D011868:Radioisotopes; D013326:Strontium Radioisotopes; D010165:Palladium